CES Honors Abbott Health Tech at Innovation Awards
FreeStyle Libre 3 leads suite of Abbott products recognized as CES 2022 Innovation Awards honorees.
Abbott's scientists and engineers work relentlessly to innovate health technologies that are helping more people live their best, fullest lives.
These innovations allow people with diabetes to monitor their glucose levels easily and accurately, without fingersticks1. They provide answers when patients are wondering if they've suffered a concussion or contracted COVID-19. And they can give doctors an inside view of the human heart.
We're proud that the Consumer Technology Association has recognized these efforts, naming Abbott's FreeStyle Libre 32 as a CES 2022 Best of Innovation award winner. Abbott's other honorees include Libre Sense, the Ultreon 1.0 software, our paired BinaxNOW COVID-19 Self Tests and NAVICA app and the i-STAT TBI plasma test.
The FreeStyle Libre 3 sensor – the world's smallest, thinnest continuous3 glucose monitor – was designed with a focus on simplicity and easy use. It can be worn up to 14 days while delivering real-time glucose readings directly to users' smartphones4. And because it's Abbott's goal to make technologies like this one affordable and accessible to the people who need them, we have kept the FreeStyle Libre 3 at the same price as previous versions5.
The CES Innovation Awards is an annual competition honoring outstanding design and engineering in consumer technology products. The Best of Innovation honor is given to the highest-rated products across more than two dozen categories. Judges rate products on aspects like engineering and functionality, aesthetic and design and what makes them unique and innovative.
The awards are a preview to CES 2022 this January in Las Vegas, where Abbott plans to be front and center. Robert Ford, our Chairman and Chief Executive Officer, will join Abbott scientists, engineers, inventors and partners to give the first-ever CES keynote address from a healthcare innovator.
We're happy to send you more stories like this one every month through our Abbott EDGE email. Sign up here. And check back issues here.
1Fingersticks are required for treatment decisions when you see Check Blood Glucose symbol, when symptoms do not match system readings, when you suspect readings may be inaccurate, or when you experience symptoms that may be due to high or low blood glucose.
2This product is not yet available in the U.S.
3Among patient-applied sensors. Date on file, Abbott Diabetes Care.
4Among leading CGM brands. Data on File, Abbott Diabetes Care.
5Based on a comparison of list prices of the FreeStyle Libre portfolio versus competitor CGM systems available worldwide. The actual cost to patients may or may not be lower than other CGM systems, depending on local reimbursement, if any.
This story was originally published on Nov. 10, 2021. It was updated on Dec. 13, 2021.
IMPORTANT SAFETY INFORMATION
The BinaxNOW™ COVID-19 Antigen Self Test is a lateral flow immunoassay intended for the qualitative detection of nucleocapsid protein antigen from SARS-CoV-2 from individuals with or without symptoms or other epidemiological reasons to suspect COVID-19 infection when tested twice over three days with at least 36 hours between tests. This test is authorized for non-prescription home use with self-collected direct anterior nasal (nares) swab samples from individuals aged 15 years or older or adult collected anterior nasal swab samples from individuals aged two years or older.
The BinaxNOW COVID-19 Ag tests have not been FDA cleared or approved. They have been authorized by the FDA under an emergency use authorization. The tests have been authorized only for the detection of proteins from SARS-CoV-2, not for any other viruses or pathogens, and are only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or authorization is revoked sooner.
Please be aware that the website you have requested is intended for the residents of a particular country or region, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions.
The website you have requested also may not be optimized for your specific screen size.
Links which take you out of Abbott worldwide websites are not under the control of Abbott, and Abbott is not responsible for the contents of any such site or any further links from such site. Abbott is providing these links to you only as a convenience, and the inclusion of any link does not imply endorsement of the linked site by Abbott.
The website that you have requested also may not be optimized for your screen size.